Lixte Completes Private Placement of Convertible Preferred Stock

Lixte Completes Private Placement of Convertible Preferred Stock

This will test the ability of LB-100, demonstrated in several animal models, to enhance the effectiveness of a widely used anticancer drug against one of the most common and devastating cancers worldwide. Third, scientists at the National Institutes of

(Visited 2 times, 1 visits today)
10
Like
Save

Comments

Comments are disabled for this post.